Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis
- PMID: 17198732
- DOI: 10.1016/j.jinf.2006.11.011
Oral step-down therapy is comparable to intravenous therapy for Staphylococcus aureus osteomyelitis
Abstract
Background: We hypothesized that regimens with an early switch to oral antibiotics are as effective as prolonged parenteral regimens for staphylococcal osteomyelitis.
Methods: We retrospectively reviewed records of adult patients with osteomyelitis caused by Staphylococcus aureus as determined by sterile site cultures, who had at least 6 months of follow-up post-therapy. The population was divided into two treatment groups: (1) an intravenous group (i.v.) that received > or = 4 weeks of parenteral therapy, and (2) a switch group that received < 4 weeks of intravenous followed by oral therapy.
Results: A total of 72 patients (36 in each group) were identified with groups evenly matched for demographic and clinical characteristics. The overall apparent cure rate was 74%; 69% for the i.v. group and 78% for the switch group (P=0.59). Apparent cure rates were similar regardless of duration of intravenous therapy: 83% < 2 weeks, 72% 2-4 weeks, 75% 4-6 weeks and 66% > or = 6 weeks (P=0.68). Among the 39 patients who received rifampin-based combinations, those treated simultaneously with vancomycin and rifampin did significantly worse than those who received other rifampin combinations (P<0.02). Overall, MRSA infections responded poorly compared to MSSA (65% apparently cured versus 83%). However, 11/14 (79%) MRSA patients who received rifampin combinations, other than vancomycin and rifampin simultaneously, were apparently cured.
Conclusions: Overall outcomes did not differ significantly between i.v. and switch groups. Given the markedly lower costs and ease of administration, prolonged oral regimens after initial intravenous therapy may be a preferred regimen for staphylococcal osteomyelitis.
Similar articles
-
A randomized clinical trial to compare fleroxacin-rifampicin with flucloxacillin or vancomycin for the treatment of staphylococcal infection.Clin Infect Dis. 2004 Nov 1;39(9):1285-92. doi: 10.1086/424506. Epub 2004 Oct 11. Clin Infect Dis. 2004. PMID: 15494904 Clinical Trial.
-
[Linezolid in the treatment of antibiotic-resistant gram-positive infections of the musculoskeletal system].Acta Chir Orthop Traumatol Cech. 2006 Oct;73(5):329-33. Acta Chir Orthop Traumatol Cech. 2006. PMID: 17140514 Czech.
-
Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin.Am J Med. 1987 Apr 27;82(4A):73-5. Am J Med. 1987. PMID: 3578332
-
Vancomycin in combination with other antibiotics for the treatment of serious methicillin-resistant Staphylococcus aureus infections.Clin Infect Dis. 2009 Oct 1;49(7):1072-9. doi: 10.1086/605572. Clin Infect Dis. 2009. PMID: 19725789 Review.
-
Addition of rifampin to vancomycin for methicillin-resistant Staphylococcus aureus infections: what is the evidence?Ann Pharmacother. 2013 Jul-Aug;47(7-8):1045-54. doi: 10.1345/aph.1R726. Epub 2013 May 28. Ann Pharmacother. 2013. PMID: 23715070 Review.
Cited by
-
Therapeutic outcome of spinal implant infections caused by Staphylococcus aureus: A retrospective observational study.Medicine (Baltimore). 2018 Oct;97(40):e12629. doi: 10.1097/MD.0000000000012629. Medicine (Baltimore). 2018. PMID: 30290637 Free PMC article.
-
Treatment of Complicated Gram-Positive Bacteremia and Infective Endocarditis.Drugs. 2025 Feb;85(2):193-214. doi: 10.1007/s40265-024-02135-z. Epub 2024 Dec 25. Drugs. 2025. PMID: 39720961 Free PMC article. Review.
-
Chronic osteomyelitis.Curr Infect Dis Rep. 2012 Oct;14(5):566-75. doi: 10.1007/s11908-012-0286-0. Curr Infect Dis Rep. 2012. PMID: 22843508
-
PSMs of hypervirulent Staphylococcus aureus act as intracellular toxins that kill infected osteoblasts.PLoS One. 2013 May 14;8(5):e63176. doi: 10.1371/journal.pone.0063176. Print 2013. PLoS One. 2013. PMID: 23690994 Free PMC article.
-
Methicillin-resistant Staphylococcus aureus: an overview of basic and clinical research.Nat Rev Microbiol. 2019 Apr;17(4):203-218. doi: 10.1038/s41579-018-0147-4. Nat Rev Microbiol. 2019. PMID: 30737488 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical